Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
360 participants
INTERVENTIONAL
2012-11-30
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence
NCT01769781
Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis
NCT00797225
Dienogest Versus GnRH-a Pre-treatment in Women With Endometriosis Undergoing IVF
NCT03142035
GnRH-a on Angiogenesis of Endometriosis
NCT06106932
Decapeptyl SR With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women
NCT00735852
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Degarelix
180 women will be treated with degarelix 120mg in one administration
degarelix
180 women will be treated with degarlix 120 mg, in only one administration covering three months
leuprolide acetate 11.25 mg/ml
180 women will be treated with leuprolide acetate 11.25 mg/ml only once covering three months
Leuprolide Acetate 11.25 MG/ML (Enantone 11,25)
180 women will be treated with leuprolide acetate11.25 only once covering three months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
degarelix
180 women will be treated with degarlix 120 mg, in only one administration covering three months
Leuprolide Acetate 11.25 MG/ML (Enantone 11,25)
180 women will be treated with leuprolide acetate11.25 only once covering three months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* previous surgery for endometriosis
Exclusion Criteria
20 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre for Endocrinology and Reproductive Medicine, Italy
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MARCO SBRACIA, MD
Role: STUDY_CHAIR
Centre for Endocrinology and Reproductive Medicine, Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Albania Spitali Amerikan
Tirana, , Albania
Nadezda Women's Health Hospital
Sofia, , Bulgaria
Cerm-Hungaria
Rome, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C06/2012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.